FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224264396> ?p ?o ?g. }

• W4224264396 endingPage "3087" @default.
• W4224264396 startingPage "3077" @default.
• W4224264396 abstract "PURPOSE Cisplatin is the main systemic treatment modality for male type II germ cell tumors (GCTs). Although generally very effective, 5%-10% of patients suffer from cisplatin-resistant disease. Identification of the driving mechanisms of resistance will enable improved risk stratification and development of alternative treatments. METHODS We developed and characterized cisplatin-resistant GCT cell line models and compared their molecular characteristics with patient samples with cisplatin resistance and/or a poor clinical outcome. Subsequently, the association between the overlapping genetic features and clinical data was assessed. Finally, we used Cox regression to determine the prognostic relevance of these features within the currently used risk classification. RESULTS Gain of chromosome 3p25.3 was detected in all cisplatin-resistant cell lines, and copy number of this region correlated with the level of resistance (R = 0.96, P = 1.5e-04). Gain of this region was detected at low frequencies in primary tumors and at higher frequencies in relapsed and/or cisplatin-resistant tumors. Chromosome 3p25.3 gain was associated with shorter progression-free survival and overall survival, with the strongest association observed in nonseminomas excluding pure teratomas. 3p25.3 gain was more frequently observed in tumors with yolk sac tumor histology and predicted adverse outcome independent of the International Germ Cell Cancer Collaborative Group risk classification and the presence of TP53/ MDM2 alterations. CONCLUSION On the basis of both in vitro analyses and clinical data, we found 3p25.3 to be strongly associated with cisplatin resistance and poor clinical outcome in male type II GCTs. Using genomic profiling, 3p25.3 status could help to improve risk stratification in male patients with type II GCT. Further characterization of this locus and underlying mechanisms of resistance is warranted to guide development of novel treatment approaches for cisplatin-resistant disease." @default.
• W4224264396 created "2022-04-26" @default.
• W4224264396 creator A5000178336 @default.
• W4224264396 creator A5008299051 @default.
• W4224264396 creator A5014887167 @default.
• W4224264396 creator A5027659301 @default.
• W4224264396 creator A5033568419 @default.
• W4224264396 creator A5049882111 @default.
• W4224264396 creator A5050740286 @default.
• W4224264396 creator A5064107781 @default.
• W4224264396 creator A5066366245 @default.
• W4224264396 creator A5068081109 @default.
• W4224264396 creator A5075450364 @default.
• W4224264396 creator A5089829688 @default.
• W4224264396 date "2022-09-10" @default.
• W4224264396 modified "2023-09-30" @default.
• W4224264396 title "Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors" @default.
• W4224264396 cites W137716526 @default.
• W4224264396 cites W1868115984 @default.
• W4224264396 cites W1972652789 @default.
• W4224264396 cites W2026084160 @default.
• W4224264396 cites W2027917454 @default.
• W4224264396 cites W2029566121 @default.
• W4224264396 cites W2042949983 @default.
• W4224264396 cites W2057882999 @default.
• W4224264396 cites W2060372099 @default.
• W4224264396 cites W2092266911 @default.
• W4224264396 cites W2097906111 @default.
• W4224264396 cites W2105044558 @default.
• W4224264396 cites W2108855472 @default.
• W4224264396 cites W2217004065 @default.
• W4224264396 cites W2419140434 @default.
• W4224264396 cites W2522030015 @default.
• W4224264396 cites W2613362156 @default.
• W4224264396 cites W2736104174 @default.
• W4224264396 cites W2758472745 @default.
• W4224264396 cites W2795441313 @default.
• W4224264396 cites W2806124857 @default.
• W4224264396 cites W2807733000 @default.
• W4224264396 cites W2952821257 @default.
• W4224264396 cites W2967416620 @default.
• W4224264396 cites W2996481446 @default.
• W4224264396 cites W3046960580 @default.
• W4224264396 cites W3119005666 @default.
• W4224264396 cites W3150204614 @default.
• W4224264396 cites W3210525240 @default.
• W4224264396 doi "https://doi.org/10.1200/jco.21.02809" @default.
• W4224264396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35442716" @default.
• W4224264396 hasPublicationYear "2022" @default.
• W4224264396 type Work @default.
• W4224264396 citedByCount "10" @default.
• W4224264396 countsByYear W42242643962022 @default.
• W4224264396 countsByYear W42242643962023 @default.
• W4224264396 crossrefType "journal-article" @default.
• W4224264396 hasAuthorship W4224264396A5000178336 @default.
• W4224264396 hasAuthorship W4224264396A5008299051 @default.
• W4224264396 hasAuthorship W4224264396A5014887167 @default.
• W4224264396 hasAuthorship W4224264396A5027659301 @default.
• W4224264396 hasAuthorship W4224264396A5033568419 @default.
• W4224264396 hasAuthorship W4224264396A5049882111 @default.
• W4224264396 hasAuthorship W4224264396A5050740286 @default.
• W4224264396 hasAuthorship W4224264396A5064107781 @default.
• W4224264396 hasAuthorship W4224264396A5066366245 @default.
• W4224264396 hasAuthorship W4224264396A5068081109 @default.
• W4224264396 hasAuthorship W4224264396A5075450364 @default.
• W4224264396 hasAuthorship W4224264396A5089829688 @default.
• W4224264396 hasBestOaLocation W42242643961 @default.
• W4224264396 hasConcept C121608353 @default.
• W4224264396 hasConcept C126322002 @default.
• W4224264396 hasConcept C143998085 @default.
• W4224264396 hasConcept C2776212926 @default.
• W4224264396 hasConcept C2776694085 @default.
• W4224264396 hasConcept C2776938808 @default.
• W4224264396 hasConcept C2778239845 @default.
• W4224264396 hasConcept C2911180711 @default.
• W4224264396 hasConcept C502942594 @default.
• W4224264396 hasConcept C71924100 @default.
• W4224264396 hasConceptScore W4224264396C121608353 @default.
• W4224264396 hasConceptScore W4224264396C126322002 @default.
• W4224264396 hasConceptScore W4224264396C143998085 @default.
• W4224264396 hasConceptScore W4224264396C2776212926 @default.
• W4224264396 hasConceptScore W4224264396C2776694085 @default.
• W4224264396 hasConceptScore W4224264396C2776938808 @default.
• W4224264396 hasConceptScore W4224264396C2778239845 @default.
• W4224264396 hasConceptScore W4224264396C2911180711 @default.
• W4224264396 hasConceptScore W4224264396C502942594 @default.
• W4224264396 hasConceptScore W4224264396C71924100 @default.
• W4224264396 hasIssue "26" @default.
• W4224264396 hasLocation W42242643961 @default.
• W4224264396 hasLocation W42242643962 @default.
• W4224264396 hasLocation W42242643963 @default.
• W4224264396 hasLocation W42242643964 @default.
• W4224264396 hasLocation W42242643965 @default.
• W4224264396 hasOpenAccess W4224264396 @default.
• W4224264396 hasPrimaryLocation W42242643961 @default.
• W4224264396 hasRelatedWork W2000161260 @default.
• W4224264396 hasRelatedWork W2003282529 @default.
• W4224264396 hasRelatedWork W2020762045 @default.

• next